Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction

Pfizer

Status and phase: Completed; Phase 2

Conditions: Impotence

Treatments: Drug: Cialis (Tadalafil); Drug: UK0369,003

Study type: Interventional

Funder types: Industry

Identifiers

NCT00174486

A3711030

Details and patient eligibility

About

Assessment of duration of action, safety & toleration of different formulations and doses of UK-369,003 and Cialis in patients with male erectile dysfunction. Patients should have previously been on PDE5 inhibitors and have been respondents to the drug. Duration of treatment is 4 weeks.

Sex: Male

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Erectile Dysfunction

Exclusion criteria

• Alpha blockers and Nitrates of any preparation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind